Compare INVE & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INVE | CNTB |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7M | 135.7M |
| IPO Year | 1997 | 2020 |
| Metric | INVE | CNTB |
|---|---|---|
| Price | $4.01 | $2.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.50 | ★ $8.67 |
| AVG Volume (30 Days) | 127.7K | ★ 173.1K |
| Earning Date | 05-13-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $60,219,000.00 | $64,000.00 |
| Revenue This Year | $22.10 | N/A |
| Revenue Next Year | $20.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.21 | N/A |
| 52 Week Low | $3.08 | $0.75 |
| 52 Week High | $5.30 | $3.82 |
| Indicator | INVE | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 40.93 |
| Support Level | $3.17 | $2.03 |
| Resistance Level | $4.07 | $2.68 |
| Average True Range (ATR) | 0.19 | 0.19 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 42.97 | 8.48 |
Identiv Inc develops specialty radio-frequency identification (RFID) and Internet of Things It (IoT) solutions that address customers' challenges and create new opportunities for them through the digitization and enhanced connectivity to the IoT. It designs, produces, and sells RFID and Bluetooth Low Energy (BLE) enabled devices, RFID inlays, tags, and labels that can be applied or incorporated into physical objects, providing them with a digital identity and the ability for customers to track, monitor, authenticate, and engage with consumers. Its IoT Business segment develops, manufactures, and supplies specialty IoT solutions tailored for the healthcare, logistics, smart packaging industries and other high-value end markets.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.